Table Of Content

Subject index of volume 103 Abuse 233 Cholinergic neurotoxin 215 Extrasynaptic receptors 366 Abuse potential 183 Chronic drug administration 204 E—10-hydroxynortriptyline 287 Acetaldehyde 74 Clonazepam 110 Acetylcholine 343 Clonidine 268 Familiar novel, fear inducing environ- ACTH 177 Clonidine-induced hypoactivity 251 ment 493 acute dystonia 503 Clonidine-induced mydriasis 251 FAST and SLOW mice 557 Adenosine antagonists A, and A, 541 Clozapine 323 Feeding 171, 366 Adrenalectomy 177 Cocaine 33, 50, 62, 297, 306, 455 Fixed interval 115 Adrenals 339 Conditioned place aversion 99 Fixed ratio 115 B-Adrenoceptors 204, 357 Conditioned place preference 99, 271 Flerobuterol 357 a%2-Adrenoceptors 251 Conditioned reinforcement 187, 197 Flumazenil 110, 384, 519 B-Adrenoceptor 351 Conditioned taste aversion 74 Flurothy!l 343 a,-Adrenoceptor 28 Conflict behavior 455 FR 121 AF64A 215 Core temperature 291 Free swim behavior 240 Aging 41, 143, 265 Corticosterone 425 Frontal cortex 41 Akathisia 138 Corticotropin-releasing factor 227, 330 Alaproclate 567 Cortisol 258 GABAsg receptors 204 Alpha-methyl-para-tyrosine 74 Cyprodime 380 Gastric damage 110 Amnesia 545 Cytidine 1 Genetic differences 244 Amphetamine 19, 62, 187, 197 Genetic selection 467 Amphetamine psychosis 480 DAGO 493 Growth hormone 140 d-Amphetamine 50, 436 Defence 449 Amygdala 473 Defense 56 Haloperidol 244 Analgesia 67, 177 Delta opioid receptor antagonist 467 Heritability 557 Animal model 415 Dependence 233 High voltage spindles 265 Anti-conflict 314 Depression 480 Hippocampus 357 Anti-convulsion 314 Development 388, 398 HMPG 287 Antidepressant 330 Diazepam 436, 455, 513, 545 Homovanillic acid 95 Antidepressant activity 524 Diazepam binding inhibitor 339 Homovanillic aicd (HVA) 551 Antidepressant drugs 251 Dissociative anesthetics 462 Hormone 443 Antidepressant treatment 357 DN—2327 314 HPLC assay 384 Antidepressants 204, 297, 306 Dopamine 78, 95, 187, 271, 323, 343, 5-HT 291, 513 Antipsychotic drugs 150, 443 480 5-HT,, agonists 529 Antipsychotics 323 Dopamine antagonists 99 5-HT,, receptor 140 Anxiety 227, 449, 541, 551 Dopamine D1 receptor 41 5-HT,-/5-HT>2 receptors 258 Anxiogenesis 473 Dopamine receptor antagonist 150 Human 223, 277 Anxiogenics 415 Dopamine receptors 6 Human drug discrimination 436 Anxiolysis 473 Dopaminergic antagonist 33 Hunger 103 Anxiolytic effect 91 Dorsal periaqueductal grey 91 HVS 567 Anxiolytics 154, 415, 529 Dorsal raphe 357 5-Hydroxyindoleacetic acid (5—HIAA) Apomorphine 19, 78 Dorsal raphe nucleus 524 551 Asrecoline 215 DPCPX 541 5-Hydroxytryptophan 258, 351 Avoidance 115 DRL 121 Hypophysectomy 177 Awakening 28 Drug abuse 154, 436 Hypothalamic paraventricular nucleus A-—69024 209 Drug discrimination 50, 67, 166 366 Az receptors 78 Drug reward 455 DSTBULET 493 IClI—204,636 323 Baboons 154 Dyskinesia 462 Indomethacin 95 Barbiturates 154 D—1 receptor 209 Intake-habits 233 Behavior 50, 67 D—1 receptors 503 Intoxication 277 Behavioral tolerance 115, 121, 268 D2 dopamine receptors 449 Intracerebral injection 91 Benzodiazepine 56, 233, 545 D—2 receptors 503 lodinated radioligand 6 Benzodiazepines 154, 529 D,-dopamine receptors 150 Ipsapirone 529 Brain regions 339 lron 138 Brotizolam 166 Early protein malnutrition 513 Isobutylmethylxanthine 388, 398 BUBU 493 EEG 375 lsoprenalineinduced drinking 351 EEG slowing 567 Caloric intake 103 Electroconvulsive shock 251, 343 Kappa opioid 129 Cannabinoid 115 Electroshock seizure threshold 380 Ketamine 462 Cannabis 277 Elevated plus-maze 91, 227, 513 Carbon monoxide 223 Enkephalinase inhibitors 467 Lateralization 19 Cerebrospinal fluid 287 Enkephalins 467 Learning 388 CGS15943A 541 Ethanol 74, 110, 227, 425 Linguopharyngeal events 462 Chlordiazepoxide 473 Ethanol-stimulated activity 557 Local injection VTA 493 p-Chlorophenylalanine 351 Ethopharmacology 56 Locomotion 297, 306, 541 Choline 343 Excitatory amino acids 91 Locomotor activity 204, 425 Cholinergic manipulation 503 Extrapyramidal side-effects 280 Locus coeruleus 330 Vill Lorazepam 83 Paracrine transmission 366 Selective opioid receptor antagonists LY171666 271 Parkinsonism drugs 162 380 Passive avoidance learning 215 Self-administration 166, 455 Marijuana 223 Peer-rearing 551 Sensitization 62 Memory 83, 143, 519 Pentobarbital 166 Sensitization to drug reward 183 Memory retention 215 Pentobarbital potentiation 314 Septum 473 Mesolimbic system 209 Peptidases inhibitor kelatorphan 493 Serotonin 143, 297, 306, 357, 388, Methadone maintenance 538 Pharmacokinetics 46, 287, 384 398 3-Methoxy-4-hydroxy-phenylgycol Phencyclidine 121 Serotonin,, receptor 524 (MHPG) 551 Physostigmine 215, 240 Sertraline 297, 306 Methylphenidate 436 Pilocarpine 567 Sex 551 Methysergide 567 Pindolol 140 Shock intensity 268 Mianserin 330, 388, 398 Pirenzepine 162 Sibutramine hydrochloride 251 Mice 244, 297, 306, 380 Place conditioning 183, 209 Sidman avoidance 268 Microdialysis 343 Plasma methadone concentrations 538 SKF38393 271 Midazolam 519, 545 Plus maze test 449 Sleep 375 MK-801 462 Positron emission tomography 41, 150 Slow wave sleep 375 Modafinil 28 Potential “atypical” neuroleptic 280 Smokers 103 Monkey brain 150 Prazosin 28 Smoking 223 Monoamines 143 Pre-exposure 74 Smoking topography 223 Morphine 67, 115, 129, 183, 407 Prolactin 46, 140, 258, 443 Social interaction 449 Morphine withdrawal 398 Prostaglandin 95 SPECT 6 Motor activity 62 Psychomotor impairment 519 Spectral analysis 375 Mu opioid 129 Psychomotor performance 83 Spontaneous activity 493 Multi-infarct dementia 1 Psychomotor stimulant effects 33 Squirrel monkey 115 Muscle relaxation 314 Psychophysiology 538 Stability 384 M, and Mz receptors 162 Purposeless chewing 503 Stimulant drugs 480 P300 1 Stimulant-induced anxiety 455 N. accumbens 209 Stress 330, 339 Naloxone 172, 177, 407 Quipazine 351 Striatum 41, 78, 187, 343 Naloxone sensitivity 129 Subjective effects 223 Naltrexone 67, 425 Submission 56 Raphe nuclei 291 Naltrindole 380 Sulpiride 443 Rat 50, 56, 78, 115, 121, 177, 183, /-Nantradol 115 187, 197, 209, 215, 291, 366, 384, NCQ 298 6 407, 415, 493, 513, 524 Tail flick latency 407 Neuroleptic 244 Rats 62, 67, 129, 240, 265, 268 Tardive dyskinesia 46 Neuroleptic drugs 138 REM sleep 375 Taste conditioning 183 Neuroleptics 46 Remoxipride 46, 443 Tetrahydroaminoacridine 240, 265 Neuropeptides 197 Restraint-stress 425 A®-tetrahydrocannabinol 172 Neuropsychological tests 545 Reward 187 THE 277 Nicotine 62, 103 Rhesus monkey 28 A®-THC 172 NMDA antagonism 462 Rhesus monkeys 166, 551 Time-Delay 121 NMDA receptor antagonist 91 Ritanserin 258 Trazodone 351 Nocturnal activity 28 Ro 5—3663 110 Tricyclic antidepressant 375 Non-benzodiazepine anxiolytics 513 Rotation 78 Tricyclic antidepressants 351 Non-response 244 Tryptophan 140 Nonsmokers 103 Turning 19 Noradrenergic 330 Salicylamide 6 Norbinaltorphimine 380 Saliva 277 Use 233 Norepinephrine 480 S(+)Aporphines 323 Nucleus accumbens 187, 197, 271 Savoxepine 280 Schedule-controlled behavior 129 Ventral tegmental area 197 8-OH—DPAT—PCPA 99 Schizophrenia 95, 280 Vibrissae 19 8-OH-DPAT 291, 524 SCH23390 41, 209 Voluntary alcohol consumption 467 Ondansetron 567 Scopolamine 83, 240 Opioid tolerance 129 Sedation 83, 519 Withdrawal 227, 407, 529 Opioids 172, 467 Selection 244 Oxotremorine 215 Selective breeding 557 Yohimbine 407